Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 126

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 126
---
 NLS and Kadimastem typically do business and the United States dollar; and •the outcome of any known and unknown litigation and regulatory proceedings. These forward -lookingstatements are based on information available as of the date of this proxy statement/prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward -lookingstatements should not be relied upon as representing the views of NLS or Kadimastem 23 as of any subsequent date, and neither NLS nor Kadimastem undertake any obligation to update forward -lookingstatements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should not place undue reliance on these forward -lookingstatements in deciding how to grant your proxy or to instruct how your vote should be cast or how you should vote your shares on the proposals set forth in this proxy statement/prospectus. As a result of a number of known and unknown risks and uncertainties, the actual results or performance of NLS may be materially different from those expressed or implied by these forward -lookingstatements. Some factors that could cause actual results to differ include: •the occurrence of any event, change or other circumstances that could delay the Merger or give rise to the termination of the Merger Agreement; •the outcome of any legal proceedings that may be instituted against NLS or Kadimastem following announcement of the proposed Merger and transactions contemplated thereby; •the inability to complete the Merger due to the failure to obtain approval of the shareholders of NLS or to satisfy other conditions to the Closing in the Merger Agreement; •the ability to obtain or maintain the listing of NLS Common Shares on Nasdaq following the Merger; •the risk that the proposed Merger disrupts current plans and operations of NLS as a result of the announcement and consummation of the transactions described herein; •the ability to recognize the anticipated benefits of the Merger, which may be affected by, among other things, competition and the ability of NLS to grow and manage growth profitably; •costs related to the Merger; •changes in applicable laws or regulations; •the occurrence of one or more high profile accidents by autonomous driving vehicles that result in lower customer demand or more stringent regulations in one or more jurisdictions in which NLS intends to operate; •NLS’s ability to raise capital; •the possibility that NLS or Kadim